Rights to Synacthen - Ownership and Business Overview

Life ScienceCompany

Rights to Synacthen Ownership

Who owns Rights to Synacthen?

Rights to Synacthen is owned by Questcor Pharmaceuticals. It was acquired on June 11, 2013.

Rights to Synacthen Business Overview

Where is Rights to Synacthen headquartered?

Rights to Synacthen is headquartered in United States.

What sector is Rights to Synacthen in?

Rights to Synacthen is a life science company.

Life Science M&A Summary in 2013

Out of 60 sectors in the Mergr database, life science ranked 8 in number of deals in 2013. The largest life science acquisition in 2013 was Onyx Pharmaceuticals - which was acquired by Amgen for $10.4B.

Join Mergr to view all 192 acquisitions of life science companies in 2013, including 26 acquisitions by private equity firms, and 166 by strategics.

Rights to Synacthen


United States,

Synacthen® and Synacthen Depot® in certain countries outside the U.S. Available in more than forty countries for multiple indications, Synacthen (tetracosactide) is a synthetic 24 amino acid melanocortin receptor agonist. Synacthen Depot is a depot formulation of Synacthen. The products are approved outside the U.S. for certain autoimmune and inflammatory conditions, but have never been developed or approved for patients in the U.S.


Company Summary

SECTOR

Life Science

 Subscribe to unlock this and 208,055
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for Rights to Synacthen

Life Science Companies , United States Companies

Related Lists for Life Science Companies

Largest Life Science Companies , Acquisitive Life Science Companies , Recently Acquired Life Science Companies , Recently Sold Life Science Companies , Private Life Science Companies , Public Life Science Companies , Acquired Life Science Companies , PE Backed Life Science Companies

Related Lists for United States Companies

Largest United States Companies , Acquisitive United States Companies , Recently Acquired United States Companies , Recently Sold United States Companies , Private United States Companies , Public United States Companies , Acquired United States Companies , PE Backed United States Companies
Mergr

Product

Company

Legal